Updates are available Correction dated 2025-03-28
Click to view Correction: https://doi.org/10.1038/s41591-025-03665-z
-
Authors
Klughammer, Johanna https://orcid.org/0000-0002-3628-9278
Abravanel, Daniel L. https://orcid.org/0000-0002-0129-1618
Segerstolpe, Åsa
Blosser, Timothy R. https://orcid.org/0000-0002-7739-922X
Goltsev, Yury https://orcid.org/0000-0003-4079-7969
Cui, Yi
Goodwin, Daniel R.
Sinha, Anubhav
Ashenberg, Orr
Slyper, Michal
Vigneau, Sébastien
Jané‐Valbuena, Judit
Alon, Shahar
Caraccio, Chiara https://orcid.org/0000-0002-3580-1348
Chen, Judy
Cohen, Ofir
Cullen, Nicole https://orcid.org/0000-0001-6541-8588
DelloStritto, Laura K.
Dionne, Danielle
Files, Janet
Frangieh, Allison
Helvie, Karla
Hughes, Melissa E.
Inga, Stephanie
Kanodia, Abhay
Lako, Ana
MacKichan, Colin
Mages, Simon https://orcid.org/0000-0003-1447-6811
Moriel, Noa
Murray, Evan
Napolitano, Sara
Nguyen, Kyleen
Nitzan, Mor https://orcid.org/0000-0003-0074-9196
Ortiz, Rebecca
Patel, Miraj
Pfaff, Kathleen L.
Porter, Caroline B. M.
Rotem, Asaf
Strauss, Sarah
Strasser, Robert
Thorner, Aaron R.
Turner, Madison
Wakiro, Isaac https://orcid.org/0000-0002-5248-4823
Waldman, Julia
Wu, Jingyi
Gómez Tejeda Zañudo, Jorge https://orcid.org/0000-0002-1092-0068
Zhang, Diane
Lin, Nancy U. https://orcid.org/0000-0003-2263-5413
Tolaney, Sara M. https://orcid.org/0000-0002-5940-8671
Winer, Eric P.
Boyden, Edward S. https://orcid.org/0000-0002-0419-3351
Chen, Fei https://orcid.org/0000-0003-2308-3649
Nolan, Garry P.
Rodig, Scott J.
Zhuang, Xiaowei
Rozenblatt-Rosen, Orit
Johnson, Bruce E.
Regev, Aviv
Wagle, Nikhil https://orcid.org/0000-0003-3332-9438
-
Funding
Funding for this research was provided by:
Conquer Cancer Foundation (17095)
Terri Brodeur Breast Cancer Foundation
The Cancer Couch Foundation; Catholic Health Foundation; Friends of Dana-Farber Cancer Institute; Hope Scarves; Jamieson Family Fund for Early Career Breast Cancer Researchers; Saverin Family Fund
European Molecular Biology Organization (ALTF 738-2017)
Human Frontier Science Program (LT000452/2019-L)
Else Kröner-Fresenius-Stiftung (2019_A70)
U.S. Department of Health & Human Services | National Institutes of Health (1P50CA168504, HHSN261100039 / HHSN26120150000, HHSN261100039 / HHSN26120150000, HHSN261100039 / HHSN26120150000)
Howard Hughes Medical Institute
Lisa Yang; John Doerr
- License Information
-
More Information
Article History
Received: 13 November 2023
Accepted: 25 July 2024
First Online: 30 October 2024
Change Date: 28 March 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41591-025-03665-z
Competing interests
: A. Regev, J.K. and D.L.A. are co-inventors on patent application number 17/156,392, filed by the Broad Institute, for inventions relating to work in this manuscript. A. Regev is a co-founder and equity holder of Celsius Therapeutics, an equity holder in Immunitas and, until 31 July 2020, a scientific advisory board (SAB) member of Thermo Fisher Scientific, Syros Pharmaceuticals, Neogene Therapeutics and Asimov. From 1 August 2020, A. Regev is an employee of Genentech and has equity in Roche. A. Rotem is an employee of AstraZeneca since September 2020 and has equity in AstraZeneca. E.S.B. co-founded a company that is exploring commercial applications of expansion microscopy. G.N. holds equity in and consults for Akoya Biosciences. J.G.T.Z. owns stocks in the biotechnology exchange-traded funds CNCR, IDNA, IBB and XBI, owns stock in Novo Nordisk and owns stock in Adaptive Biotechnologies, 2seventy bio and bluebird bio. J.J-V. is a contractor at Genentech since 2021. M.S. is a contractor at Genentech since November 2020. O.R.-R. is a co-inventor on patent applications filed by the Broad Institute for inventions related to single-cell genomics. She has given numerous lectures on the subject of single-cell genomics to a wide variety of audiences and, in some cases, has received remuneration to cover time and costs. O.R.-R. is an employee of Genentech since 19 October 2020 and has equity in Roche. S.J.R. is a member of the SAB of Immunitas Therapeutics and receives research funding from Bristol Myers Squibb and Kite/Gilead. X.Z. is a co-founder of and consultant for Vizgen. The other authors declare no competing interests.
